Botanix Pharmaceuticals Limited
BXPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $5,412 | $378 | $1,692 | $378 |
| % Growth | 1,333.2% | -77.7% | 347.6% | – |
| Cost of Goods Sold | $2,563 | $1,209 | $2,674 | $3,403 |
| Gross Profit | $2,849 | -$831 | -$982 | -$3,025 |
| % Margin | 52.6% | -220.1% | -58.1% | -800.4% |
| R&D Expenses | $6 | $138 | $835 | $978 |
| G&A Expenses | $5,645 | $3,450 | $5,886 | $762 |
| SG&A Expenses | $52,646 | $30,022 | $5,456 | $1,523 |
| Sales & Mktg Exp. | $29,597 | $8,862 | -$430 | $762 |
| Other Operating Expenses | $0 | $0 | $1,558 | $0 |
| Operating Expenses | $52,652 | $30,160 | $7,849 | $2,501 |
| Operating Income | -$49,803 | -$30,991 | -$8,831 | -$6,496 |
| % Margin | -920.3% | -8,207.5% | -522.1% | -1,718.9% |
| Other Income/Exp. Net | -$5,705 | $103 | $428 | $1,029 |
| Pre-Tax Income | -$55,508 | -$30,888 | -$8,403 | -$5,467 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55,508 | -$30,888 | -$8,403 | -$5,467 |
| % Margin | -1,025.7% | -8,180.2% | -496.7% | -1,446.6% |
| EPS | -0.03 | -0.017 | -0.005 | -0.004 |
| % Growth | -74.1% | -214.8% | -42.1% | – |
| EPS Diluted | -0.03 | -0.017 | -0.005 | -0.004 |
| Weighted Avg Shares Out | 1,873,058 | 1,816,948 | 1,564,428 | 1,438,727 |
| Weighted Avg Shares Out Dil | 1,873,000 | 1,816,948 | 1,564,400 | 1,438,727 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,148 | $68 | $42 |
| Interest Expense | $4,638 | $0 | $8 | $7 |
| Depreciation & Amortization | $1,146 | $1,118 | $64 | $8 |
| EBITDA | -$49,798 | -$30,853 | -$8,401 | -$2,759 |
| % Margin | -920.2% | -8,171% | -496.7% | -730% |